Connection

Merryn Voysey to Antibodies, Viral

Back to Details
This is a "connection" page, showing publications Merryn Voysey has written about Antibodies, Viral.
Merryn Voysey
Connection Strength
0.038
Antibodies, Viral
  1. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021 08; 8(8):e474-e485.
    View in: PubMed
    Score: 0.023
  2. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
    View in: PubMed
    Score: 0.006
  3. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 08 15; 396(10249):467-478.
    View in: PubMed
    Score: 0.005
  4. Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year. JAMA. 2017 03 14; 317(10):1075-1077.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.